James Campbell

Proteome-based plasma biomarkers for Alzheimer's disease

Abdul Hye, Steven Lynham, Madhav Thambisetty et al. · Brain · 2006 · 474 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma et al. · Nature Communications · 2018 · 447 citations · Full text

Medicine, Molecular Biology, Oncology +17

Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease

Madhav Thambisetty, Andrew Simmons, Latha Velayudhan et al. · Archives of General Psychiatry · 2010 · 403 citations · Full text

Life Sciences, Neurology, Neuroscience +17

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Chris T. Williamson, Rowan Miller, Helen N. Pemberton et al. · Nature Communications · 2016 · 387 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity

Ilirjana Bajrami, Jessica Frankum, Asha Konde et al. · Cancer Research · 2013 · 368 citations · Full text

Medicine, Oncology, Pharmacology +17